Introduction
Protective adaptive immunity relies on cellular and humoral immune responses. Through presenting processed antigens on their MHC molecules, dendritic cells (DCs) are primarily responsible for initiating T cell-mediated cellular immunity, which is also required for T cell-dependent antibody responses. Germinal centers (GCs) are specialized microarchitecture within the follicles in the secondary lymphoid organs, where B cells undergo affinity maturation, selection and proliferation. Follicular helper T cells (Tfh) are a subset of CD4 + T cells marked by their expression of inhibitory receptor PD-1 and chemokine receptor CXCR5 and play important roles in the development of GC B cells by providing differentiation, survival and proliferation signals (Crotty, 2011; Ma et al., 2012) . While co-maturation between GC B cells and Tfh is required to stably maintain both subsets (Baumjohann et al., 2013; Deenick et al., 2010; Qi et al., 2008) , it has been shown that early instructive signals from antigen-bearing DCs are both necessary and sufficient to prime Tfh differentiation (Baumjohann et al., 2011; Choi et al., 2011; Deenick et al., 2010; Goenka et al., 2011) .
For the development of antibody responses, DCs not only promote Tfh differentiation but also directly support B cell survival and class-switching through their expression of B cell stimulatory ligands such as BAFF and APRIL (MacLennan and Vinuesa, 2002) . Moreover, DCs are also important as antigen carriers that provide the initial antigen-specific receptor signaling to the cognate B cells in the lymph nodes (LNs) (Qi et al., 2006) . Indeed, in vivo antigen delivery to receptors specifically expressed by DCs can trigger robust class-switched antibody production even without an adjuvant (Chappell et al., 2014; Xu and Banchereau, 2014) . Importantly, antigen delivery strategies targeting distinct DC subsets seem to result in increased antigen-specific antibody titers regardless of the DC subset targeted (Lahoud et al., 2011; Yao et al., 2015) , suggesting that multiple DC subsets are capable of inducing antibody production (Chappell et al., 2014) . However, the regulatory mechanism that counteracts the ability of DCs to induce humoral responses is less well understood.
In mouse skin, there are at least three distinct skin-resident DC subsets at the steady-state including epidermal Langerhans cells (LCs), Langerin + CD103 + dermal DCs (DDCs) and Langerin -CD11b + DDCs (Kaplan et al., 2012) . CD301b + DCs are a major subset of migratory CD11b + DDCs that express the highest levels of PD-1 ligands, PD-L1 and PD-L2, among DC subsets in the skin-draining LNs (dLNs) (Gao et al., 2013; Kumamoto et al., 2009 Kumamoto et al., , 2013 Murakami et al., 2013) . In addition to the dermis, CD301b + DCs are found in the submucosa of gastrointestinal, respiratory and reproductive tract (Denda-Nagai et al., 2010; Kumamoto et al., 2013) . By using Mgl2-DTR mice in which one of the endogenous Mgl2 alleles (encoding CD301b protein) are replaced with a diphtheria toxin receptor (DTR)-GFP cassette, we have shown previously that inducible depletion of CD301b + DCs by injecting diphtheria toxin (DT) results in impaired Th2 differentiation of antigen-specific CD4 + T cells following footpad immunization of protein antigen with Th2 adjuvants as well as after subcutaneous infection with Nippostrongylus brasiliensis. Notably, despite the impaired Th2 differentiation, mice that lack CD301b + DCs developed intact antibody responses against N. brasiliensis infection . In addition, recent studies have expanded the role of CD301b + DCs beyond the Th2 differentiation program, by demonstrating that they are required for IL-17 production from dermal gdT cells following epidermal infection with Candida albicans, or from Th17 cells with intranasal infection with Streptococcus pyogenes (Kashem et al., 2015b; Linehan et al., 2015) . Here, we describe the role of CD301b + DC in the regulation of humoral immunity. We show that To investigate this issue, Kumamoto et al. studied both normal mice and mice in which the particular types of dendritic cell can be depleted. The investigation revealed that dendritic cells that produce a protein called CD301b suppress the activity of T follicular helper cells. In mice with few CD301b-producing dendritic cells, the activity of the T follicular helper cells was higher than in normal mice, resulting in the hyperactivation of the B cells. This also led to the antibodies behaving in exaggerated ways, as can occur in autoimmune diseases. Other experiments that depleted some other types of dendritic cell -but not those that produce CD301b -completely abolished the antibody response of the mice.
Future experiments are now needed to investigate exactly how the CD301b-producing dendritic cells block the activity of T follicular helper cells. Exploiting this mechanism could help to design treatments for autoimmune diseases. À1, +1 and +3. Mice were immunized with 50 mg papain in 20 ml phosphate-buffered saline (PBS) with or without (No OVA at 1˚) 5 mg OVA in the footpad. On day 14, OVA (50 mg in 100 ml PBS) was injected retro-orbitally without adjuvant. Sera were harvested on days À1, +14 and +21. OVAspecific antibody titers were detected by ELISA. Bars indicate mean ± S.E.M. calculated from three (WT and Mgl2-DTR) or two (No OVA at 1˚) individual mice. Representative data from three independent experiments are shown. (c,d) Mgl2-DTR mice were treated with DT and immunized with 5 mg OVA and 50 mg papain in the footpad as in a (DT Day À1/+2). Alternatively, WT or Mgl2-DTR mice were immunized with OVA and papain on day 0, then treated with DT on days five and eight (DT Day +5/+8). All mice received a boost immunization with OVA in PBS on day 14. Sera were collected in two independent experiments from total of 5-6 mice per group. (e,f) Mgl2-DTR mice were treated i.p. with DT or PBS and painted with whole cell lysates of house dust mite (HDM) for three times as shown in e. HDM-specific antibody titers were tested by ELISA against the whole cell HDM lysates (f). Data were collected from five animals in each group and are representative of two independent experiments. Bars indicate mean ± S.E.M. n.s., not significant, *p<0.05, **p<0.01, ***p<0.001 by two-tailed Student's t-test. Figure 1a) . Immunization of Mgl2-DTR mice depleted of CD301b + DCs resulted in greatly enhanced production of OVA-specific class-switched antibodies (Figure 1b) . The increased antibody titers were evident on day 14 after a single immunization and enhanced following a systemic secondary exposure to the same antigen without an adjuvant (Figure 1b) . However, the antibody titers were not elevated when CD301b + DCs were depleted five days postimmunization ( Figure 1c,d ). These results indicated that the presence of CD301b + DCs during the early phase of primary immunization has a negative and lasting impact on humoral immunity. To test the role of CD301b + DCs in antibody production against another allergen, we sensitized CD301b + DC-depleted mice epicutaneously by painting whole extracts from house dust mite Dermatophagoides pteronyssinus (Figure 1e ). Although this needle-free immunization protocol induced minimal amount of antibodies in WT mice even after multiple exposure to the antigen, CD301b + DC-depleted mice generated robust antibody production ( Figure 1f) . These results indicate that the enhanced antibody responses in CD301b + DC-depleted mice are found in response to subcutaneous papain immunization and to epicutaneous allergen exposure.
Depletion of CD301b + DCs enhances antigen-specific antibody production in response to intraperitoneal immunization
To examine if antibody responses primed in organs other than the skin were also affected by the depletion of CD301b + DCs, we next immunized Mgl2-DTR mice intraperitoneally (i.p) with OVA and alum, another type 2 adjuvant that requires CD301b + DCs for Th2 differentiation . We observed a trend for enhanced antibody production in CD301b + DC-depleted animals, which was likely a result of the depletion of CD301b + DC in the peritoneal cavity and its draining mediastinal LN (Kool et al., 2008) (Figure 2) . As in the skin-dLNs, CD301b + DCs in the peripheral organs expressed CD11b and MHCII but not Ly6C, but were nearly absent from the spleen ( (Meredith et al., 2012; Satpathy et al., 2012 Figure 3) . To account for any potential effects of the DT treatment, we treated Mgl2-DTR mice with a nontoxic DT mutant, CRM197 (Malito et al., 2012) , and used this group as the undepleted control. Increasing doses of the antigen did not overcome suppression of antibody responses by CD301b + DCs (Figure 3b) Mgl2-DTR mice were treated with 0.5 mg DT or its inactive mutant CRM197 (CRM) on days -1 and +2 and immunized on day 0 with 50 mg papain plus indicated amount of OVA in the footpad. All mice received i.p. injection of 10 mg OVA without adjuvant on day 14 and sera were harvested on day 21 for OVA-specific antibody ELISA. (c) WT and Mgl2-DTR mice were treated with 0.5 mg DT on days À1 and +2 and immunized in the footpad with 5 mg OVA without any adjuvant on day 0 (top). Alternatively, lethally-irradiated WT mice were reconstituted with Mgl2-DTR (DTR only), WT (WT only) or 1:1-mixture of WT and Mgl2-DTR (WT+DTR) BM cells, then immunized with 5 mg OVA without adjuvant (bottom). All mice received i.p. injection of 10 mg OVA without adjuvant on day 14 and day 21, and sera were harvested on day 21 and day 28 for OVA-specific IgG1 ELISA. Bars indicate mean ± S.E.M. calculated from 4-11 individual mice. n.s., not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by twotailed Student's t-test. All statistics indicate comparison to the undepleted (CRM-treated, WT or WT only BM chimera) control shown in each panel. DOI: 10.7554/eLife.17979.006 adjuvants ( Figure 3c) . A possible explanation of these results is that the CD301b + DCs killed by DT release endogenous materials capable of serving as an adjuvant to stimulate antibody responses to OVA. To test this possibility, we next immunized lethally-irradiated WT mice reconstituted with a 1:1 mixture of WT and Mgl2-DTR bone marrow (BM) cells. In order to avoid any DT-induced adjuvanticity masked by the presence of exogenous adjuvant, we took advantage of the adjuvant-free immunization approach. Although antibody levels in BM chimeric mice were generally lower than in nonirradiated mice, prime (day 0) and 2 boosts (days 14 and 21) with adjuvant-free OVA resulted in significantly increased OVA-specific antibody titers in mice reconstituted only with Mgl2-DTR BM cells ( Figure 3c ). In contrast, mice reconstituted with a mixture of WT and Mgl2-DTR yielded minimal antibody production ( Figure 3c) 
Depletion of CD301b + DCs broadens antibody specificity and enhances affinity
To address the potential impact of the depletion of CD301b + DCs on the specificity and affinity of the antibodies, we next immunized the mice with papain plus OVA conjugated with 4-hydroxyl-3-nitrophenyl acetyl in 1:16 ratio (NP 16 OVA), followed by a secondary immunization with NP 16 OVA without adjuvant through a systemic route ( Figure 5a ). WT mice immunized with this protocol developed a significant amount of NP 16 OVA-specific antibodies, albeit to a lesser extent than the CD301b + DC-depleted mice. However, consistent with previous studies showing preferential development of hapten-specific rather than carrier-specific antibodies upon immunization with haptenated proteins (Palm and Medzhitov, 2009; Shimizu et al., 2007) , the majority of the NP 16 OVA-specific antibodies produced in WT mice were directed to the hapten, as anti-OVA antibody responses were undetectable ( Figure 5b ). In contrast, CD301b + DC-depleted mice developed significantly higher amount of antibodies against all epitopes examined. Notably, unlike WT animals, CD301b + DC-depleted mice also produced antibodies specific to the OVA carrier, indicating that the specificity of the antibodies were broadened in these mice ( Figure 5b ). In addition, the ratio between the binding of the antibodies to bovine serum albumin (BSA) conjugated with high (NP 34 BSA) and low (NP 4 BSA) numbers of NP suggested that antibodies in immunized CD301b + DC-depleted mice underwent similar (IgG1) or even slightly higher (IgG2b) levels of affinity maturation compared to the WT mice ( Figure 5c ). These results indicate that CD301b + DCs suppress the magnitude, breadth and affinity of antibodies.
Depletion of CD301b + DCs enhances autoreactive antibodies
Based on the results above, we questioned why such antibody-suppressive DCs exist in mice. One possibility is that the CD301b + DCs are needed to suppress the generation of autoreactive antibodies. Indeed, transient depletion of CD301b + -DCs for 9 days resulted in the development of anti-nuclear IgG antibodies 60 days later ( Figure 6 ). These results indicate that CD301b + DCs play a key role in suppressing the emergence of autoantibodies.
CD301b + DCs regulate expansion of antigen-specific germinal center B cells
To understand the cellular basis for the enhanced antibody production generated in the absence of CD301b + DCs, we next analyzed the cellular composition in the popliteal dLN (right) and non-draining (nd) (left) popliteal LN during the priming phase after a single immunization with OVA and papain in the right footpad ( Figure 7a ). Consistent with our previous report, the size of the dLNs at three days post-immunization in CD301b + DC-depleted animals was much smaller than in undepleted controls, likely due to impaired screening and retention of naïve CD4 + T cells We next examined the phenotype of B cell subsets in the dLNs 14 days after a single immunization with OVA and papain in the footpad (Figure 7c) . In CD301b + DC-depleted animals, an increased fraction of B cells that downregulated surface IgD receptor and bound to soluble fluorescently-labeled OVA protein was found, indicative of OVA-specific activated B cells (Figure 7d,f) . Some IgD -cells expressed a plasma cell marker CD138 (Figure 7e,g ). We also observed an expansion of the CD38 -GL7 + germinal center (GC) B cell fraction, while the CD38 + GL7 -naïve/memory fraction (Taylor et al., 2015) was significantly reduced (Figure 7h-j) . Notably, OVA-specific B cells were 
WT 
CD301b + DCs but not other migratory DCs suppress antibody responses
The results thus far indicated that CD301b + DCs suppress Tfh and GC B cell expansion. Although CD301b-driven DTR-GFP expression is detectable only in a subset of Langerin -CD11b + DCs, Figure 7 continued immunized on day 0 with 5 mg OVA with 50 mg papain as in Figure 2 . On day 14, dLNs were harvested and cells were stained for the cell-surface markers as well as for their binding to Alexa488-conjugated OVA protein (A488-OVA 
LN-resident, but not migratory, DCs promote Tfh, GC B and antibody responses
We next sought to determine which DC subsets are responsible for promoting Tfh and GC B cell development. To first address the role of two other major migratory DCs, we used huLangerin-DTR; Mgl2-DTR and msLangerin-DTR;Mgl2-DTR mice, in which CD301b + DCs and LCs, and Langerin 
CD301b + DCs express PD-1 ligands
PD-1 is an inhibitory receptor that is upregulated in a fraction of activated T cells (Jin et al., 2011) . PD-1 is also a marker of Tfh cells (Baumjohann et al., 2011; Choi et al., 2011; Crotty, 2011; Glatman Zaretsky et al., 2009; Haynes et al., 2007) . CD301b + DCs express high levels of a PD-1 ligand PD-L2 (B7-DC) (Gao et al., 2013; Kumamoto et al., 2013; Murakami et al., 2013) . Indeed, within the non-lymphocyte population in the skin-dLNs, CD301b + DCs express highest levels of both PD-1 ligands PD-L1 (B7-H1) and PD-L2 (Figure 10a ). More than 90% of all PD-L1 + PD-L2 + non-lymphocytes were MHCII hi migratory DCs, of which more than 40% consisted of CD301b + DCs. In addition, a significant number of PD-L1 + PD-L2 + DCs that do not express CD301b were also present, which was minimally affected by the depletion of CD301b + DCs (Figure 10-figure supplement   1a ).
PD-L1 blockade enhances expansion of Tfh and GC B cells only in the presence of CD301b + DCs
To test if PD-1 ligands contribute to the suppression of Tfh and GC B cell expansion by CD301b + DCs, we treated WT or CD301b + DC-depleted mice with anti-PD-L1 or anti-PD-L2 blocking injection of 10 mg OVA in PBS without adjuvant on day 14. Serum OVA-specific IgG1 on day 21 was detected by ELISA. Bars indicate mean ± S.E.M. calculated from 3-6 individual mice in each group. Representative data from 2-3 independent experiments are shown. (e) Mgl2-DTR and CD11c-DTR; Mgl2-DTR mice were immunized and boosted as in a, except that the mice were treated with a single dose of 125 ng DT on day À1. Sera were harvested on day 21 from three independent experiments and OVA-specific IgG1 was detected by ELISA. Bars indicate mean ± S.E.M. calculated from five (Mgl2-DTR) and three (Mgl2-DTR;CD11c-DTR) individual mice. n.s., not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by two-tailed Student's t-test. All statistics indicate comparison to the undepleted (WT or no DT) control shown in each panel except in b and are shown by colormatched asterisks where applicable. (f) WT mice and mice that carry Mgl2-DTR, huLang-DTR and/or msLang-DTR in their genetic construct were treated with DT and immunized as in a, then LNs were harvested on day seven. Tfh and GC B cell percentages in dLNs. Data were pooled from 2-3 independent experiments per group. (g) Mgl2-DTR mice were treated with DT and immunized as in a. Mice received i.p. injections of 50 mg anti-Gr-1 (a-Gr1) or Rat IgG2a isotype control antibodies every other day starting on day two. Left non-draining (L) or right draining (R) popliteal LNs were harvested on day seven and analyzed for GC B and Tfh cells. Data were pooled from two individual experiments per group. Each dot indicates an individual mouse. n.s., not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by two-tailed Student's t-test. Bars indicate means ± S.E.M. DOI: 10.7554/eLife.17979.013
The following figure supplement is available for figure 9: monoclonal antibodies (mAbs) during the priming phase (Figure 10b) . We first confirmed that the blockade did not directly deplete CD301b + DCs (Figure 10-figure supplement 1b) . In the dLN in WT mice, the PD-L1 but not PD-L2 blockade significantly enhanced the GC B cell and Tfh cell development ( Figure 10c,d and Figure 10-figure supplement 2a,b) . In Mgl2-DTR mice, however, anti-PD-L1 blocking mAb did not exert further enhancement of the GC B cell and Tfh cell development ( Figure 10c,d and Figure 10-figure supplement 2a,b) . Since PD-L1 expression was still intact in the residual DC subsets (Figure 10-figure supplement 1a) , these data indicate that PD-L1 in the residual cells does not have suppressive function on GCB or Tfh differentiation during priming. In the contralateral ndLNs, neither PD-L1 nor PD-L2 significantly enhanced the GC B cell development in either WT or Mgl2-DTR mice (Figure 10-figure supplement 2c) .
The blockade of PD-1, PD-L1, or PD-L2 in WT mice during the priming with OVA and papain resulted in significant increases in OVA-specific antibody production (Figure 10-figure supplement  2d) . Consistent with the GC B cell expansion, antibody responses were enhanced by anti-PD-L1 antibody treatment only in the presence of CD301b + DCs, whereas the PD-L2 blockade further increased OVA-specific IgG2b (Figure 10e,f) . (Gao et al., 2013; Kashem et al., 2015a; Kumamoto et al., 2013; Murakami et al., 2013) . Taken together, these results indicate that, Tfh and Th2 responses can be uncoupled, with the CD301b + DCs as the pivotal cell type carrying out suppressive vs. supportive roles, respectively. Tfh responses are also regulated by the Tfr cells (Sage et al., 2013) . We describe a separate mechanism dedicated to suppressing Tfh responses mediated by the CD301b + DCs. These nonredundant Tfh regulatory mechanisms likely control Tfh responses at distinct stages. CD301b + DCmediated suppression occurs within the first few days of primary immune response, while the Tfr entry into the reactive LN occurs after 7 days of immunization (Sage et al., 2013) . These two phases of Tfh regulation likely provide complementary mechanisms of Tfh control. For instance, Tfr cells are important in producing high affinity antibody responses that are devoid of self-reactivity (Pratama and Vinuesa, 2014) . Regulation of Tfh responses at early phases by CD301b + DCs may be critical in preventing excess antibody responses to foreign and self-antigens, which can lead to host pathology through complement fixation, and deposition of antibody-immune complex (Rouse and Sehrawat, 2010) . In fact, we detected antinuclear autoantibodies following transient depletion of CD301b + DCs. Future studies are needed to determine the consequence of CD301b + DC depletion on the development of autoimmune disease. CD301b + DCs are the major subset of CD11b + migratory DCs that most efficiently take up the antigen and bring to the dLNs within one day after immunization with papain. In addition, CD301b + DCs are required for optimal screening and activation of naïve CD4 + T cells within the dLNs . Our current study showed that, despite the reduction in the amount of antigen available within the dLNs and the impaired recruitment of naïve lymphocytes to the dLN in the first three days of immunization . Similarly, CD301b + DCs did not suppress IgG2b antibody generated by strong type 1 immunity induced by high doses of CpG ( Figure 4c ). These results suggest that pathogens can overcome CD301b + DC-dependent suppression of antibody responses, likely through continuous antigen presentation (Baumjohann et al., 2013; Deenick et al., 2010) and through engagement of strong inductive signals through pattern recognition receptors including TLRs (Pasare and Medzhitov, 2005) .
Our study pointed to the role of LN-resident DCs in supporting Tfh-inductive functions, as evidenced by the diminished antibody responses in CD11c-DTR;Mgl2DTR mice but not those depleted of migrant DCs. The DC subset specifically responsible for inducing Tfh remains to be identified. Alternatively, our results suggest the possibility that any DC subset is sufficient to induce Tfh cells in the absence of the negative regulation exerted by CD301b + DCs (Lahoud et al., 2011; Yao et al., 2015) . Recent studies have indicated that the therapeutic effect of PD-L1 blockade in chronic infection by HIV and malaria is mediated in part by inducing more Tfh cells that help B cells to produce pathogen-specific neutralizing antibodies (Butler et al., 2012; Cubas et al., 2013) . Similarly, continuous blockade as well as genetic deletion of PD-L1 was shown to enhance Tfh and GC B cell expansion upon type 2 immunization (Hams et al., 2011) . In these studies, due to the timing of the PD-L1 blockade (past Tfh priming), activated B cells were the major source for the PD-L1 relevant to the memory Tfh population. In contrast, our results clearly demonstrated that the transient depletion of CD301b + DCs during the priming phase had a significant positive impact on humoral immunity that persisted even after the secondary immunization. Our study shows that the PD-L1 blockade cannot further enhance Tfh and GC B responses when CD301b + DCs are depleted. Consistently, a recent report demonstrated that neonatal blockade of PD-L1 that is preferentially expressed by CD11b + DCs in the lung results in exaggerated antibody production later in life during adulthood, suggesting the contribution of a similar DC subset that suppresses humoral immunity through PD-L1 expression (Gollwitzer et al., 2014) . As many other cell types express PD-L1 in vivo, dissection of the relative and temporal contributions of PD-L1 in Tfh blockade by specific cell types will require generation of new tools. Our results are consistent with an inhibitory role for PD-L1 and/or PD-L2 for antibody responses described in some studies (Hams et al., 2011; Ishiwata et al., 2010) , but not in others (GoodJacobson et al., 2010; Sage et al., 2013) . For instance, GC B cell and IgG1 induction in response to NP-CGG immunization in PD-1 knockout mice are comparable or even slightly better than WT mice (Good-Jacobson et al., 2010) , consistent with our data. In contrast, the PD-1 deficient mice contain higher percentages of Tfr but not Tfh (Sage et al., 2013) , and Tfh cells isolated from PD-1 deficient mice had impaired cytokine responses (Good-Jacobson et al., 2010) . Differences observed in our study versus others using genetically deficient mice might be explained by the fact that we used transient blockade of PD-1 ligands with mAbs. However, since PD-1-independent mechanism is also possible, the precise mechanism by which CD301b + DCs regulate GC B needs to be elucidated in future studies.
Autoreactive antibody responses are controlled at the level of the bone marrow in developing B cells (central tolerance) as well as at the level of the peripheral tissues (peripheral tolerance). Autoreactive early immature B cells recognizing self-antigens are eliminated in the BM in a cell-intrinsic manner. Once in the periphery, mature B cells that react against autoantigens are suppressed by regulatory T cells (Tregs) in a cell-extrinsic manner (Meffre and Wardemann, 2008 Topalian et al., 2012) . While PD-L1 blockade with an antibody is not a practical solution to boost prophylactic vaccine approaches due to the inhibitory costs associated with the antibody, future development of an affordable PD-L1 antagonist might enable implementation of this concept into vaccine design. An optimal combination of the adjuvant to activate B cell affinity maturation and a blocker of inhibition imposed by the CD301b + DC may provide an ideal setting for generating robust protective humoral responses.
Materials and methods

Mice
WT C57BL/6N (B6) and CD45.1 (B6.SJL-Ptprc a Pepc b /BoyJ) OT-II mice were maintained in our specific pathogen-free facility. Mgl2 DTReGFP/DTReGFP mice (RRID:MGI:5510785) were developed as previously described and bred with B6 mice to gain heterozygotic Mgl2-DTR mice (RRID:MGI:5510786). huLangerin-DTR mice were bred with B6 or Mgl2 DTReGFP/DTReGFP homozygotes. Transgene-bearing offspring were screened as previously described (Bobr et al., 2010) . msLangerin-DTR mice (B6.129S2-Cd207 tm3(DTR/GFP)Mal /J; RRID:IMSR_JAX:016940) were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained as homozygotes. For depletion experiments, the homozygotic msLangerin-DTR mice were crossed onto Mgl2 DTReGFP/DTReGFP homozygotes to gain heterozygotic msLangein-DTR;Mgl2-DTR (Mgl2 +/DTReGFP ;Cd207 +/DTRGFP ) offspring.
To generate CD11c-DTR;Mgl2-DTR mice, CD11c-DTR mice (B6.FVB-Tg(Itgax-DTR/EGFP)57/Lan/J; RRID:IMSR_JAX:004509) were crossed with Mgl2 DTReGFP/DTReGFP homozygotes, then transgene-bearing offspring were screened with the following primers to amplify the boundary between the Itgax promoter and the DTReGFP cassette: CAGAGCCTGCTTCTGTTCTCCAG and GTTGCTGGTTCCAG-CAGCTAG. For generating chimeric mice, WT B6 mice were irradiated with two doses of 475 cGy (total 950 cGy) and reconstituted with 1 x 10 6 WT, Mgl2-DTR or 1:1 mixture of WT and Mgl2-DTR BM cells. The mice were used for experiments more than eight weeks after the BM transplantation.
In most experiments, 2-6 month-old female mice were used. However, due to mouse availability, mice of both sexes were used in experiments involving mice with huLangerin-DTR or CD11c-DTR construct. No gross difference was noted between male and female in those experiments. All animal protocols (protocol number 10365) were approved by and performed in accordance with guidelines set by the Institutional Animal Care and Use Committee at Yale University.
Immunization
DT or its non-toxic mutant CRM197 (List Biological Laboratories, Campbell, CA) was injected i.p. (0.5 mg in 0.5 ml PBS per dose, except for CD11c-DTR;Mgl2-DTR mice in which only a single dose of 125 ng per mouse was given to avoid toxicity) at indicated time-points. For antibody titer analyses, mice were immunized in the hind footpad on day 0 with indicated dose of OVA (Ovalbumin Low Endo, Worthington Biochemical Corporation, Lakewood, NJ) with 50 mg papain (SigmaAldrich, St. Louis, MO), CpG-2216 (TriLink Biotechnologies, San Diego, CA), or LPS (from Salmonella enterica serotype typhimurium, Sigma). Alternatively, mice were immunized i.p. with 10 mg OVA suspended in 50% alum in PBS (Imject Alum, Thermo Scientific, Waltham, MA). The immunization was boosted on day 14 by injecting 10 mg OVA in 100 ml PBS i.p. or retro-orbitally without adjuvant. In some experiments, NP 16 OVA (Biosearch Technologies, Petaluma, CA) was used for immunization. In experiments involving BM chimeric mice, an additional boost was given on day 21. For LN cell analyses, mice were immunized on day 0 with 5 mg OVA plus 50 mg papain in 20 ml PBS in the right hind footpad and popliteal LNs were harvested at indicated time-points. Where indicated, TCR-transgenic CD4 + T cells were isolated from the spleen and LNs of naïve CD45.1 (Ptprc a )-expressingOT-II mice by CD4 + T cell isolation kit (Miltenyi Biotec, San Diego, CA) and transferred (5-10 Â 10 5 cells followed by incubation with HRP-conjugated subclass-specific detection antibodies. Serum antinuclear IgG antibodies were captured by Mouse ANA Total Ig ELISA Kit (Alpha Diagnostics, San Antonio, TX) and detected by HRP-conjugated goat anti-mouse IgG Fcg Fragment (Jackson ImmunoResearch). HRP binding was visualized by 1xTMB ELISA Substrate Solution (eBioscience) and the absorbance at 450 nm was detected by a plate reader (Model 680, Bio-Rad, Hercules, CA). For calculating EC 50 and the maximal absorbance (A max ), data from each mouse were fit to Y = A max *X/ (EC 50 +X) + NS*X + Background, where Y is observed absorbance and X is serum dilution, with the following restraints: 0 < A max < 3.5, 0 < EC 50 < 1, 0 < NS < 2, and 0 < Background < 0.1. EC 50 was assumed as 1.0 where calculated A max was < 0.2. Affinity maturation was examined by taking the ratio between EC 50 for NP 4 BSA binding and EC 50 for NP 34 BSA binding and expressed as the negative log value of the ratio.
Antibody responses against house dust mite (HDM)
Crude lysates of D. pteronyssinus were purchased from Greer Laboratories (Lenoir, NC). For sensitization, about 1x2 cm 2 area of upper back skin was shaved with a razor on day À1 and painted with 80 mg (as protein concentration in 0.1 ml PBS) of lysates on days 0, 7 and 14. HDM-specific IgG1 and IgG2b were measured in the day 20 sera by ELISA using plates coated with HDM lysates. For detecting HDM-specific IgE, plates coated with anti-mouse IgE (R35-72, BD Biosciences) were incubated with the sera, then further incubated with biotinylated HDM lysates.
Statistics
All statistical analyses were performed by two-tailed Student's t-test with Welch's correction and all bars in graphs indicate means ± S.E.M., unless otherwise indicated. n.s., not significant (p!0.05), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
